Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Clinical Trials

aTyr Securities Suits Intensify as New Filing Expands Class Period Ahead of Dec. 8 Deadline

The complaints center on claims that executives overstated efzofitimod's ability to eliminate steroid use in the EFZO‑FIT trial.

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

First New Antimalarial in Decades Tops 97% Cure in Phase III as Novartis Seeks Approval

FDA Names Richard Pazdur to Lead Drug Review Center

New aTyr Class Action Expands Investor Window After EFZO-FIT Failure

Novo Nordisk Raises Metsera Bid to $10 Billion, Outpacing Pfizer’s $8.1 Billion Counter

FDA Rejects Biohaven’s Vyglxia for Spinocerebellar Ataxia

MoonLake Investors Face Dec. 15 Lead-Plaintiff Deadline as Securities Case Advances in SDNY

Sarepta Shares Plunge After ESSENCE Phase 3 Miss in Duchenne Trial

MoonLake Investors Face Dec. 15 Lead-Plaintiff Deadline in SDNY Securities Case

Roche’s Giredestrant Plus Everolimus Extends PFS in Phase 3 evERA for ER-Positive, HER2-Negative Breast Cancer

Praxis Drug Succeeds in Two Phase 3 Essential Tremor Trials, FDA Filing Planned

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials

Amgen Reports Repatha Cuts First-Event Risk in Primary-Prevention Trial

Moonlake Shares Plunge on Mixed Phase 3 Results for Hidradenitis Drug

Eli Lilly Halts Diabetes Arm of Bimagrumab Obesity Trial Weeks After Launch

FDA Grants Priority Review for Enhertu Plus Pertuzumab in First-Line HER2-Positive Metastatic Breast Cancer

Roivant’s Brepocitinib Succeeds in 52-Week Dermatomyositis Phase 3 as Companies Target 2026 FDA Filing

AstraZeneca’s Fasenra Misses Primary Endpoint in COPD Phase III Trial

Sanofi’s Amlitelimab Meets Phase 3 Goals in Eczema as Shares Fall on Tepid Efficacy